Recent Quotes
My Watchlist
Indicators
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Anika Therapeutics Inc. - Common Stock (NQ:ANIK)

20.66 +1.38 (+7.16%)
Streaming Delayed Price Updated: 2:53 PM EDT, Aug 3, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 136,051
Open 19.59
Bid (Size) 20.55 (900)
Ask (Size) 20.79 (100)
Prev. Close 19.28
Today's Range 19.59 - 21.11
52wk Range 7.920 - 19.29
Shares Outstanding 14,828,456
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Anika Therapeutics Q2 Earnings Call Highlights ↗
Anika Therapeutics (NASDAQ:ANIK) reported higher second-quarter revenue, expanded gross margin and its strongest adjusted EBITDA performance since 2020, as international commercial growth and... 
Via MarketBeat
Topics Earnings
Anika Therapeutics (NASDAQ:ANIK) Soars on Q2 Earnings Beat, Revenue and EPS Top Estimates ↗
Via Chartmill
Topics Earnings

Performance

YTD
+121.0%
+121.0%
1 Month
+28.9%
+28.9%
3 Month
+42.0%
+42.0%
6 Month
+114.5%
+114.5%
1 Year
+135.6%
+135.6%

More News

Read More
News headline image
Anika to Issue Second Quarter 2026 Financial Results on Wednesday, July 29, 2026
From Anika Therapeutics Inc.
Via GlobeNewswire
News headline image
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Anika Therapeutics Inc.
Via GlobeNewswire
Anika Therapeutics Inc (NASDAQ:ANIK) Soars on Q1 Earnings and Revenue Beat ↗
Via Chartmill
ANIKA THERAPEUTICS INC (NASDAQ:ANIK) Delivers Decisive Q4 2025 Earnings Beat, Sparking Share Rally ↗
Via Chartmill
Topics Earnings
News headline image
TELA Bio Announces Strategic Board Refreshment with Four Highly Experienced Commerical Leaders to Accelerate Growth and Drive Path to Profitability; The Company Also Reports Preliminary First Quarter 2026 Revenues
From TELA Bio, Inc.
Via GlobeNewswire
News headline image
Anika (ANIK) Q1 2026 Earnings Transcript ↗
Via The Motley Fool
News headline image
Anika (ANIK) Q2 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Anika (ANIK) Q4 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Xilio Therapeutics Appoints Cheryl R. Blanchard, Ph.D. to its Board of Directors
From Xilio Therapeutics, Inc.
Via GlobeNewswire
News headline image
Anika to Issue First Quarter 2026 Financial Results on Wednesday, April 29, 2026
From Anika Therapeutics Inc.
Via GlobeNewswire
News headline image
Organogenesis Clears Major FDA Hurdle: Path to First Non-Surgical Biologic for Knee Osteoarthritis Widens
Via MarketMinute
News headline image
Telix Strengthens Board with Additional Director Appointments
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Anika Therapeutics Inc.
Via GlobeNewswire
News headline image
Anika To Present at the Canaccord Genuity 2026 Musculoskeletal Conference
From Anika Therapeutics Inc.
Via GlobeNewswire
News headline image
Anika to Issue Fourth Quarter and Year-End 2025 Financial Results on Thursday, February 26, 2026
From Anika Therapeutics Inc.
Via GlobeNewswire
News headline image
ANIKA INVESTIGATION REMINDER: Bragar Eagel & Squire, P.C. Reminds Anika Therapeutics Investors to Contact the Firm Regarding the Ongoing Investigation on Behalf of Anika Stockholders
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
ANIK INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Anika Therapeutics, Inc.
From Kirby McInerney LLP
Via Business Wire
News headline image
Anika Therapeutics Announces Leadership Transition
From Anika Therapeutics Inc.
Via GlobeNewswire
News headline image
ANIK Investigation: Investors Encouraged to Contact Kirby McInerney LLP
From Kirby McInerney LLP
Via Business Wire
News headline image
Anika Therapeutics, Inc. INVESTIGATION: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud on behalf of Investors ANIK
From Kirby McInerney LLP
Via GlobeNewswire
News headline image
Anika (ANIK) Q3 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Anika Therapeutics Inc (NASDAQ:ANIK) Reports Q3 2025 Earnings Beat and Positive Regulatory Milestone ↗
Via Chartmill
Topics Earnings
News headline image
Anika Therapeutics Reports Filing of Final PMA Module for Hyalofast® Cartilage Repair Scaffold and Data from U.S. Pivotal FastTRACK Phase III Study
From Anika Therapeutics Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Anika Therapeutics Inc. - Common Stock publicly traded?
Yes, Anika Therapeutics Inc. - Common Stock is publicly traded.
What exchange does Anika Therapeutics Inc. - Common Stock trade on?
Anika Therapeutics Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Anika Therapeutics Inc. - Common Stock?
The ticker symbol for Anika Therapeutics Inc. - Common Stock is ANIK on the Nasdaq Stock Market
What is the current price of Anika Therapeutics Inc. - Common Stock?
The current price of Anika Therapeutics Inc. - Common Stock is 20.66
When was Anika Therapeutics Inc. - Common Stock last traded?
The last trade of Anika Therapeutics Inc. - Common Stock was at 08/03/26 02:53 PM ET
What is the market capitalization of Anika Therapeutics Inc. - Common Stock?
The market capitalization of Anika Therapeutics Inc. - Common Stock is 306.36M
How many shares of Anika Therapeutics Inc. - Common Stock are outstanding?
Anika Therapeutics Inc. - Common Stock has 306M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.